MedTrace Logo

Investigation of the Proportion of Human Epidermal Growth Factor Receptor 2 Protein Overexpression of Gastric Adenocarcinoma and Prognostic Effect of HER2, and Analysis of Practice Pattern of Herceptin Use in Stage IV Gastric Cancer

NCT02136836 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 860

Last updated 2014-05-13

No results posted yet for this study

Summary

The objective of this study is to investigate the proportion of HER2 overexpression in gastric cancer patients group, to evaluate the relation of HER2 overexpression with prognosis, and to analyze the proportion of herceptin applied to patients in clinical field. Furthermore, the investigators are going to reevaluate the clinical benefit of Herceptin for survival prolongation compared to chemotherapy only.

Conditions

  • Stomach Neoplasms

Sponsors & Collaborators

  • Yonsei University

    lead OTHER

Principal Investigators

  • Jae Yong Cho, M.D.,Ph.D. · Gangnam Severance Hospital, Yonsei University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2015-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02136836 on ClinicalTrials.gov